Skip to main content
Erschienen in: PharmacoEconomics 9/2016

01.09.2016 | Original Research Article

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland

verfasst von: Susanne Schmitz, Laura McCullagh, Roisin Adams, Michael Barry, Cathal Walsh

Erschienen in: PharmacoEconomics | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Decisions on reimbursement of health interventions in many jurisdictions are informed by health technology assessments (HTAs). Historically, the focus of these has often been cost effectiveness or cost utility, while other criteria were considered informally. More recently, there has been an increasing interest in the formal incorporation of additional criteria using multi-criteria decision analysis. Such an approach has not yet formally been part of decision-making policy in Ireland.

Objective

The objective of this analysis is to demonstrate that cost effectiveness is not the only criterion influencing reimbursement decisions in Ireland. Furthermore, the aim is to reveal criteria that may have informally influenced reimbursement decisions in the past.

Methods

A list of potential criteria was identified based on the literature, national guidelines and experience of the national HTA agency. Information on each of these criteria was sought for every assessment conducted in Ireland up to July 2015. A logistic regression was fitted to the data to identify influential parameters. Model selection was performed using the Bolasso method.

Results

Thirteen criteria were considered in the analysis. Two members of the HTA review team assessed the performance of the interventions against these criteria. Model selection suggests that the incremental cost-effectiveness ratio and quality of evidence could be important drivers of reimbursement recommendations in Ireland. Less important drivers suggested include the year of assessment, the level of uncertainty, as well as safety and tolerability.

Conclusion

The analysis demonstrates that recommendations for or against the reimbursement of technologies in Ireland are not only driven by cost effectiveness. This highlights the need for more formal inclusion of criteria in the process, to improve transparency and ensure consistency.
Literatur
2.
Zurück zum Zitat Johri M, Norheim OF. Can cost-effectiveness analysis integrate concerns for equity? Systematic review. Int J Technol Assess Health Care. 2012;28(2):125–32.CrossRefPubMed Johri M, Norheim OF. Can cost-effectiveness analysis integrate concerns for equity? Systematic review. Int J Technol Assess Health Care. 2012;28(2):125–32.CrossRefPubMed
3.
Zurück zum Zitat Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–81.CrossRefPubMed Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–81.CrossRefPubMed
5.
Zurück zum Zitat Dakin HA, Devlin NJ, Odeyemi IA. “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. Health Policy. 2006;77(3):352–67.CrossRefPubMed Dakin HA, Devlin NJ, Odeyemi IA. “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. Health Policy. 2006;77(3):352–67.CrossRefPubMed
6.
Zurück zum Zitat Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–52.CrossRefPubMed Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–52.CrossRefPubMed
7.
Zurück zum Zitat Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Mak. 2008;28(5):713–22.CrossRef Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Mak. 2008;28(5):713–22.CrossRef
8.
Zurück zum Zitat Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29(4):456–65.CrossRefPubMed Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29(4):456–65.CrossRefPubMed
9.
Zurück zum Zitat Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.CrossRefPubMed Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.CrossRefPubMed
10.
Zurück zum Zitat Rotter JS, Foerster D, Bridges JF. The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):711–23.CrossRefPubMed Rotter JS, Foerster D, Bridges JF. The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):711–23.CrossRefPubMed
11.
Zurück zum Zitat Guindo LA, Wagner M, Baltussen R, Rindress D, van Til J, Kind P, et al. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Eff Resour Alloc. 2012;10(1):9.CrossRefPubMedPubMedCentral Guindo LA, Wagner M, Baltussen R, Rindress D, van Til J, Kind P, et al. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Eff Resour Alloc. 2012;10(1):9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat. 2004;32(2):407–99.CrossRef Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat. 2004;32(2):407–99.CrossRef
14.
15.
Zurück zum Zitat R-Core-Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. R-Core-Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
18.
Zurück zum Zitat Goetghebeur M, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32(2):376–88.CrossRef Goetghebeur M, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32(2):376–88.CrossRef
19.
Zurück zum Zitat Baltussen R, Ten Asbroek A, Koolman X, Shrestha N, Bhattarai P, Niessen L. Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan. 2007;22(3):178–85.CrossRefPubMed Baltussen R, Ten Asbroek A, Koolman X, Shrestha N, Bhattarai P, Niessen L. Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan. 2007;22(3):178–85.CrossRefPubMed
20.
Zurück zum Zitat Vargas V, Poblete S. Health prioritization: the case of Chile. Health Aff. 2008;27(3):782–92.CrossRef Vargas V, Poblete S. Health prioritization: the case of Chile. Health Aff. 2008;27(3):782–92.CrossRef
21.
Zurück zum Zitat Jehu-Appiah C, Baltussen R, Acquah C, Aikins M, Amah d’Almeida S, Bosu WK, et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value Health. 2008;11(7):1081–7.CrossRefPubMed Jehu-Appiah C, Baltussen R, Acquah C, Aikins M, Amah d’Almeida S, Bosu WK, et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value Health. 2008;11(7):1081–7.CrossRefPubMed
23.
Zurück zum Zitat Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated approach. Heidelberg: Springer; 2002.CrossRef Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated approach. Heidelberg: Springer; 2002.CrossRef
Metadaten
Titel
Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland
verfasst von
Susanne Schmitz
Laura McCullagh
Roisin Adams
Michael Barry
Cathal Walsh
Publikationsdatum
01.09.2016
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0406-z

Weitere Artikel der Ausgabe 9/2016

PharmacoEconomics 9/2016 Zur Ausgabe